TLR4 and hepatitis B virus infection: In particular, TLR4 ligand MPLA is licensed for human use in HPV and hepatitis B vaccines and TLR9 ligand, CpG-B, has been extensively tested in vaccine trials for hepatitis B and anthrax, where it was shown to be able to enhance specific antibody responses.